Darunavir-Ethanolate-TMC114-Ethanolate-DataSheet-生命科学试剂-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDarunavir EthanolateCat. No.: HY-17041CAS No.: 635728-49-3Synonyms: TMC114 (Ethanolate)分式: CHNOS分量: 593.73作靶点: HIV; HIV Protease作通路: Anti-infection; Metabolic Enzyme/Protease储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 mo

2、nths-20C 1 month溶解性数据体外实验 DMSO : 50 mg/mL (84.21 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.6843 mL 8.4213 mL 16.8427 mL5 mM 0.3369 mL 1.6843 mL 3.3685 mL10 mM 0.1684 mL 0.8421 mL 1.6843 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。体内实验请根据您的实验动物和

3、给药式选择适当的溶解案，配制前请先配制澄清的储备液，再依次添加助溶剂(为保证实验结果的可靠性，体内实验的作液，建议您现现配，当天使；澄清的储备液可以根据储存条件，适当保存；以下溶剂前的百分 指该溶剂在您配制终溶液中的体积占)：1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.21 mM); Clear solution2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (4.21 mM); Cl

4、ear solution1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (4.21 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Darunavir Ethanolate (TMC114 Ethanolate)种于治疗和预防HIV/AIDS的HIV蛋酶抑制剂。对野型HIV-1蛋酶的Ki值为1 nM。IC50 & Target Ki: 1 nM (WT HIV-1 protease) 1体外研究

5、Darunavir is a broad-spectrum potent inhibitor active against HIV-1 clinical isolates with minimal cytotoxicity.Darunavir forms hydrogen bonds with the conserved main-chain atoms of Asp29 and Asp30 of the protease.These interactions are proposed to be critical for the potency of this compound agains

6、t HIV isolates that areresistant to multiple protease inhibitors 1. In an in vitro study in MT-2 cells, the potency of darunavir isgreater than that of saquinavir, amprenavir, nelfinavir, indinavir, lopinavir and ritonavir. Darunavir is primarilymetabolized by the hepatic cytochrome P450 (CYP) enzym

7、es, primarily CYP3A. The boosting dose ofritonavir acts an an inhibitor of CYP3A, thereby increasing darunavir bioavailability 2.体内研究 Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needsto be combined with ritonavir, which increases the bioa

8、vailability to 82% 3.户使本产品发表的科研献 J Neuroimmune Pharmacol. 2019 Jul 23.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Tie Y, et al. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical

9、strains. J Mol Biol. 2004 Apr 23;338(2):341-52.2. McKeage K, et al. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503.3. Bhalekar MR, et al. In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir. Drug Deliv. 2016Sep;23(7):2581-2586.McePdfHeightCaution: Product has not been fully validated for medi